This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed.
Learn more about the Dal-GenE-2 (Dal-302) trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
